(Q45755625)

15 December 2017

title

Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus (English)

1 reference

15 December 2017

1 reference

1 reference

0 references

1 reference

J R Ungo

1

1 reference

15 December 2017

D Jones

2

1 reference

15 December 2017

D Ashkin

3

1 reference

15 December 2017

E S Hollender

4

1 reference

15 December 2017

D Bernstein

5

1 reference

15 December 2017

A P Albanese

6

1 reference

15 December 2017

A E Pitchenik

7

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 June 1998

1 reference

15 December 2017

American Journal of Respiratory and Critical Care Medicine

published in

1 reference

15 December 2017

volume

157

1 reference

15 December 2017

issue

6 Pt 1

1 reference

15 December 2017

page(s)

1871-1876

1 reference

15 December 2017

Epidemiology of tuberculosis in the United States, 1985 through 1992.

cites work

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.9711039

Adverse effects of drugs used in the management of opportunistic infections associated with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.9711039

Epidemiology of hepatitis C virus. A preliminary study in volunteer blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.9711039

Transmission of hepatitis C virus--route, dose, and titer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.9711039

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.9711039

Toxic hepatitis with isoniazid and rifampin. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.9711039

Anti-tuberculous therapy and acute liver failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.9711039

Actions of cytokines on the immune response and viral interactions: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.9711039

HIV-proteinase inhibitors in the management of HIV-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.9711039

Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.9711039

Histopathology of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.9711039

The interferons. Mechanisms of action and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.9711039

The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.9711039

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.9711039

Interferon--a major regulator of natural killer cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.9711039

21 January 2018

Therapy of Hepatitis C

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.9711039

Isoniazid induction of antinuclear antibodies. A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.157.6.9711039

10.1164/AJRCCM.157.6.9711039

21 January 2018

Identifiers

DOI

1 reference

15 December 2017

1 reference

15 December 2017